Literature DB >> 22540160

Cerebrospinal fluid levels of high-mobility group box 1 and cytochrome C predict outcome after pediatric traumatic brain injury.

Alicia K Au1, Rajesh K Aneja, Michael J Bell, Hülya Bayir, Keri Feldman, P David Adelson, Ericka L Fink, Patrick M Kochanek, Robert S B Clark.   

Abstract

High-mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that is passively released from damaged and necrotic cells, and actively released from immune cells. In contrast, cytochrome c is released from mitochondria in apoptotic cells, and is considered a reliable biomarker of apoptosis. Thus, HMGB1 and cytochrome c may in part reflect the degree of necrosis and apoptosis present after traumatic brain injury (TBI), where both are felt to contribute to cell death and neurological morbidity. Ventricular cerebrospinal fluid (CSF) was obtained from children admitted to the intensive care unit (ICU) after TBI (n=37). CSF levels of HMGB1 and cytochrome c were determined at four time intervals (0-24 h, 25-48 h, 49-72 h, and>72 h after injury) using enzyme-linked immunosorbent assay (ELISA). Lumbar CSF from children without TBI served as controls (n=12). CSF HMGB1 levels were: control=1.78±0.29, 0-24 h=5.73±1.45, 25-48 h=5.16±1.73, 49-72 h=4.13±0.75,>72 h=3.80±0.90 ng/mL (mean±SEM). Peak HMGB1 levels were inversely and independently associated with favorable Glasgow Outcome Scale (GOS) scores at 6 mo (0.49 [0.24-0.97]; OR [5-95% CI]). CSF cytochrome c levels were: control=0.37±0.10, 0-24 h=0.69±0.15, 25-48 h=0.82±0.48, 49-72 h=1.52±1.08,>72 h=1.38±1.02 ng/mL (mean±SEM). Peak cytochrome c levels were independently associated with abusive head trauma (AHT; 24.29 [1.77-334.03]) and inversely and independently associated with favorable GOS scores (0.42 [0.18-0.99]). In conclusion, increased CSF levels of HMGB1 and cytochrome c were associated with poor outcome after TBI in infants and children. These data are also consistent with the designation of HMGB1 as a "danger signal." Distinctly increased CSF cytochrome c levels in infants and children with AHT and poor outcome suggests that apoptosis may play an important role in this unique patient population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22540160      PMCID: PMC3408241          DOI: 10.1089/neu.2011.2171

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  49 in total

1.  Release of cytochrome c into the extracellular space contributes to neuronal apoptosis induced by staurosporine.

Authors:  Barbara Ahlemeyer; Susanne Klumpp; Josef Krieglstein
Journal:  Brain Res       Date:  2002-05-03       Impact factor: 3.252

2.  The danger model: a renewed sense of self.

Authors:  Polly Matzinger
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

3.  Intracranial pressure-monitoring systems in children with traumatic brain injury: combining therapeutic and diagnostic tools.

Authors:  Jennifer Exo; Patrick M Kochanek; P David Adelson; Stephanie Greene; Robert S B Clark; Hülya Bayir; Stephen R Wisniewski; Michael J Bell
Journal:  Pediatr Crit Care Med       Date:  2011-09       Impact factor: 3.624

4.  Inflicted traumatic brain injury: relationship of developmental outcome to severity of injury.

Authors:  L Ewing-Cobbs; M Prasad; L Kramer; S Landry
Journal:  Pediatr Neurosurg       Date:  1999-11       Impact factor: 1.162

5.  Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo.

Authors:  A Renz; W E Berdel; M Kreuter; C Belka; K Schulze-Osthoff; M Los
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

6.  Differential expression of apoptotic protease-activating factor-1 and caspase-3 genes and susceptibility to apoptosis during brain development and after traumatic brain injury.

Authors:  A G Yakovlev; K Ota; G Wang; V Movsesyan; W L Bao; K Yoshihara; A I Faden
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

7.  The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway.

Authors:  Stefania Gardella; Cristina Andrei; Denise Ferrera; Lavinia V Lotti; Maria R Torrisi; Marco E Bianchi; Anna Rubartelli
Journal:  EMBO Rep       Date:  2002-09-13       Impact factor: 8.807

8.  Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 1: Introduction.

Authors:  P David Adelson; Susan L Bratton; Nancy A Carney; Randall M Chesnut; Hugo E M du Coudray; Brahm Goldstein; Patrick M Kochanek; Helen C Miller; Michael D Partington; Nathan R Selden; Craig R Warden; David W Wright
Journal:  Pediatr Crit Care Med       Date:  2003-07       Impact factor: 3.624

9.  Circulating soluble cytochrome c in liver disease as a marker of apoptosis.

Authors:  Z Ben-Ari; H Schmilovotz-Weiss; A Belinki; O Pappo; J Sulkes; M G Neuman; E Kaganovsky; B Kfir; R Tur-Kaspa; T Klein
Journal:  J Intern Med       Date:  2003-08       Impact factor: 8.989

10.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.

Authors:  Paola Scaffidi; Tom Misteli; Marco E Bianchi
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

View more
  37 in total

Review 1.  The role of autophagy in acute brain injury: A state of flux?

Authors:  Michael S Wolf; Hülya Bayır; Patrick M Kochanek; Robert S B Clark
Journal:  Neurobiol Dis       Date:  2018-04-26       Impact factor: 5.996

Review 2.  The far-reaching scope of neuroinflammation after traumatic brain injury.

Authors:  Dennis W Simon; Mandy J McGeachy; Hülya Bayır; Robert S B Clark; David J Loane; Patrick M Kochanek
Journal:  Nat Rev Neurol       Date:  2017-02-10       Impact factor: 42.937

Review 3.  A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis?

Authors:  Ruchira M Jha; Patrick M Kochanek
Journal:  Curr Neurol Neurosci Rep       Date:  2018-11-07       Impact factor: 5.081

Review 4.  White matter damage after traumatic brain injury: A role for damage associated molecular patterns.

Authors:  Molly Braun; Kumar Vaibhav; Nancy M Saad; Sumbul Fatima; John R Vender; Babak Baban; Md Nasrul Hoda; Krishnan M Dhandapani
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-05-19       Impact factor: 5.187

5.  Minocycline Attenuates High Mobility Group Box 1 Translocation, Microglial Activation, and Thalamic Neurodegeneration after Traumatic Brain Injury in Post-Natal Day 17 Rats.

Authors:  Dennis W Simon; Rajesh K Aneja; Henry Alexander; Michael J Bell; Hülya Bayır; Patrick M Kochanek; Robert S B Clark
Journal:  J Neurotrauma       Date:  2017-08-22       Impact factor: 5.269

Review 6.  The danger zone: Systematic review of the role of HMGB1 danger signalling in traumatic brain injury.

Authors:  Taylor M Parker; Austin Huy Nguyen; Joshua R Rabang; Arun-Angelo Patil; Devendra K Agrawal
Journal:  Brain Inj       Date:  2016-11-07       Impact factor: 2.311

Review 7.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

Review 8.  The HMGB1-RAGE Inflammatory Pathway: Implications for Brain Injury-Induced Pulmonary Dysfunction.

Authors:  Daniel J Weber; Yohance M Allette; David S Wilkes; Fletcher A White
Journal:  Antioxid Redox Signal       Date:  2015-05-14       Impact factor: 8.401

Review 9.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 10.  Pathophysiology and treatment of cerebral edema in traumatic brain injury.

Authors:  Ruchira M Jha; Patrick M Kochanek; J Marc Simard
Journal:  Neuropharmacology       Date:  2018-08-04       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.